CLRB - Cellectar Biosciences, Inc. Price-to-Projected Revenue Ratio

Cellectar Corp (CLRB) - corporate logo

Rising competition in radiopharmaceuticals and pressure from industry behemoths create risks for the sector. Examining the expected P/S valuation on GURU.Markets reveals a downward trend, where the current parameter equals . However, patents for PDC-conjugates protect the niche of Cellectar Biosciences (CLRB), and the completion of final clinical trials for the macroglobulinemia drug confirms the company's high investment readiness.

Cellectar Biosciences Inc - CLRB Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Cellectar Corp (CLRB)

- market price and analyst price targets:
Price Chart Cellectar Biosciences, Inc.|CLRB - Price Target Chart
- market capitalization statistics:
Market Value Cellectar Corp|CLRB - Total Enterprise Value
- book value of equity indicators:
Book Value per Share Cellectar Biosciences|CLRB - Book Value of Business|Market Cap to Net Assets Ratio cellectar.com|CLRB - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Cellectar Biosciences|CLRB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Cellectar Biosciences|CLRB - Company Cumulative Indebtedness|Debts to Book Capitalization Cellectar Corp|CLRB - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cellectar Biosciences|Quick Liquidity cellectar.com
- financial results and valuation multiples details:
CLRB - Final Profit|Projected Future Earnings Cellectar Biosciences|CLRB - P/E Multiple|Future Price to Earnings Cellectar|CLRB - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Cellectar Corp|CLRB - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Cellectar Biosciences|CLRB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth cellectar.com|CLRB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cellectar Biosciences
- revenue and sales proceeds data:
CLRB - Company Revenue|Company Projected Revenue Cellectar Biosciences, Inc.|CLRB - Price-to-Revenue Ratio|Forward P/S Multiple Cellectar Corp
General company analysis:Cellectar Biosciences, Inc. CLRB
Manufactured products of cellectar.com

To objectively assess the asset's value, the manager must compare current market capitalization with discounted revenue expectations, which helps identify overvaluation risks should forecasts deviate. An analysis of Cellectar Biosciences (CLRB) forward P/S helps determine the sensitivity threshold of share prices to the commercialization rates of Iopofosine and the impact of FDA regulatory decisions within the radiopharmaceutical sector.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lixte Biotechnology, Inc. (LIXT)|Price-to-Projected Revenue Ratio Citius Pharmaceuticals Inc.|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|Forward Price-to-Revenue Multiple G1 Therapeutics|KRON (Kronos Bio Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kintara Pharma KTRA|Price-to-Projected Revenue Ratio Oncternal Therapeutics (ONCT)|Price-to-Projected Revenue Ratio PRTG (portagebiotech.com)